Abionyx Pharma: to benefit from a 1ME grant from Bpifrance
This aid will contribute to the financing of studies on the CER-001 drug candidate, and will be reimbursable at 0% interest on condition of success from the last quarter of 2026, until the first quarter of 2031.
Abionyx Pharma notes that the preclinical studies conducted to date have been a success, and would like to thank Bpifrance for its long-standing support.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction